Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor

Figure 4 Enhancement of mediated radioimmunotherapeutic effects on BxPC-3 xenografts in combination with BEZ235 treatment. A: Tumor volume changes expressed as the ratio of the volume on the indicated day and the volume on the day treatment began. Compared with the control vehicle administration (light blue squares), single administration of ⁹⁰Y-ITGA6B4 (2.8 MBq) alone (red diamonds) or oral administrations of BEZ235 alone (35 mg/kg, 5 d/wk for 6 wk) (blue triangles) resulted in impaired tumor growth. When ⁹⁰Y-ITGA6B4 treatment was administered in conjunction with BEZ235 (orange squares), further reduction in tumor volume ratio was observed indicating enhanced therapeutic effect upon combined treatment. Values represent mean ± SD, ^aP < 0.05 (⁹⁰Y-ITGA6B4 + BEZ235 vs⁹⁰Y-ITGA6B4), ^bP < 0.05 (90Y-ITGA6B4 + BEZ235 vs BEZ235), ^cP < 0.05 (⁹⁰Y-ITGA6B4 + BEZ235 vs Vehicle, ⁹⁰Y-ITGA6B4 vs Vehicle); B: Average mouse body weight did not differ significantly among all 4 groups. Vertical orange arrowhead indicates the day of 90Y-ITGA6B4 injection. Values represent mean ± SD, n = 6.